Note: This material includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors including adverse economic conditions, delays in new product launch, pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively. Financial Results for the Second Quarter of Fiscal Year 2015 ending March 2016 November 25. 2015 TRANS GENIC INC. ~ For Healthy and Affluent Lives of People Around The World ~ http://www.transgenic.co.jp
36
Embed
Financial Results2015/11/25 · available to management and subject to significant risks and uncertainties. Actual financial results may differ materially Actual financial results
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Note: This material includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors including adverse economic conditions, delays in new product launch, pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively.
Financial Results for the Second Quarter of Fiscal Year
2015 ending March 2016
November 25. 2015 TRANS GENIC INC.
~ For Healthy and Affluent Lives of People Around The World ~
Consolidated Financial Results Highlight of 2Q-FY2015
Unit: thousand yen 2Q-FY2015 2Q-FY2014 Change
Net Sales 717,376 751,584 34,208
Cost of Sales 526,403 563,838 37,435
Gross Profit of Sales 190,973 187,746 ▲3,227
SG&A expenses (R&D expenses)
317,280
(20,485)
321,032
(29,126)
3,752
(8,641)
Operating Profit/Loss ▲126,307 ▲133,285 ▲6,978
Ordinary Profit/Loss ▲132,516 ▲145,310 ▲12,794
Net Profit/Loss ▲130,713 ▲104,990 25,723
Sales amount marked 104.8% over the previous year. Aiming for further growth in the second half year.
Both CRO business and pathological diagnostics business did well, and maintained an upward trend.
Operating profit decreased due to greater burden of fixed cost in association with scale expansion, however final profit /loss improved by recognizing tax effect with profit structure.
Sales and profit decreased due to shortage of retained earnings carried forward at the start of the fiscal year, however expect to improve in the second half
Promoting revenue expansion by active introduction of new technologies and enhancement of mouse model lineup
Performance Summary: Contract Research Organization Business
Revenue increased substantially due to steady order acquisition (increased more than two hundred million yen over previous year including backlog of orders)
Operating profit/loss improved drastically in association with increased revenue
Both sales and profit decreased due to poor performance in private genetic analysis service
Further streamlining of business management, expanding contract analysis service, as well as focusing on acquiring orders for drug discovery support service toward individualized medicine with high future growth potential
Genomics 414,699 424,000 9,301 Secure orders for genome editing technology-related service, strengthen sales of mouse model, introduce new mouse model
CRO 799,183 880,000 80,817 Expand business with existing customers, acquire new customers, develop contract non-clinical study service using disease mouse model
Advanced medical 369,779 446,000 76,221
Integrate analysis technologies of gene
analysis business division, streamline
operations
Pathological diagnostics 396,779 400,000 3,221 launch new service
Reconciliation ▲21,272 ー 21,272
Operating expenses 1,934,861 2,110,000 175,139
Operating profit 23,693 40,000 16,307
Ordinary profit 9,396 35,000 25,604
Net profit 17,824 18,000 176
It is believed that business performance of FY2015-2Q generally worked out as planned and order acquisition is satisfactory, considering TRANS GENIC’s second-half oriented business style. Maintaining this trend in order to reach sales of 2.15 billion yen, expand surplus in operating/ordinary profit, and improve the bottom line.
Drug discovery bio-venture companies with unique and predominant technologies
Collaborative development Sales
support
Generate additional value of seeds for drug discovery
Venture capital firms, industrial companies
Fund raising Corporate alliance
Management guidance (such as advice for
preparing business plan), dispatch of human
resources
To accomplish Medium-term business planning, actively-participating in management/ development of drug discovery bio-venture companies as “unique business group providing full support in drug discovery“, and aim to improve
corporate value.
TRANS GENIC Group
Drug discovery
Improve corporate value
Acquiring new technologies
Licensing to pharmaceutical companies
Business Topics
Capital and Business Alliance with Medicinal Chemistry Pharmaceuticals, Co., Ltd.
『JP3816512』granted in Japan 『US7,700,741』granted in USA 『JP4608432 』granted in Japan(diagnosis for early stage cancer)
『US9134313 』granted in USA(diagnosis for early stage cancer)
Jun. 2006 Apr. 2010 Nov. 2010 Sep. 2015
『JP4319700』granted in Japan 『US8,883,972』granted in USA
Jun. 2009 Nov. 2014
Cancer marker in urine: Assay system for cancer diagnosis using urine sample
Pancreatic cancer marker: Antibody and its diagnostic application
『AU778719 』 granted in Australia『US7,312,075 』 granted in USA 『EP1201759』 granted in Europe 『ZL00812904.5』 granted in China 『HK1048830B』 granted in Hong Kong 『JP4664554』 granted in Japan『ZL200510084464.6』granted in China 『US8,722,408』granted in USA
『ZL2003801028324』granted in China 『AU2003277620』granted in Australia『EP1559318』granted in Europe 『JP4426728』granted in Japan 『KR941905』granted in Korea 『JP4478577』granted in Japan 『US7,919,674』granted in USA 『ZL200710193915.9 』granted in China『HK1124363B』 granted in Hong Kong 『JP5080597』granted in Japan
『AU778719 』 granted in Australia『US7,312,075 』 granted in USA 『EP1201759』 granted in Europe
Apr. 2005 Dec. 2007 Mar. 2010
『ZL2003801028324』granted in China 『AU2003277620』granted in Australia 『EP1559318』granted in Europe 『JP4426728』granted in Japan 『KR941905』granted in Korea
Jul. 2008 Feb. 2009 Apr. 2009 Jan. 2010 Mar. 2010
Our Intellectual Property
Status of the Major Patents (Oct. 2010)
Exchangeable gene-
trap mouse technology
GANP® mouse
technology
Cancer marker in urine: Assay system for cancer diagnosis using urine sample
Pancreatic cancer marker: Antibody and its diagnostic application